Background
Tislelizumab, toxicities, death, tumour
SECONDARY, TUMOUR
Programmed cell death protein-1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1), are immune checkpoint proteins that play critical roles in the immune modulation of tumour progression in a wide variety of tumour types [Although treatment with PD-1/PD-L1 inhibitor monotherapy provides improved responses, prolonged survival and fewer toxicities compared with conventional therapies in many tumour types, a significant proportion of patients do not respond or eventually relapse on treatment due to secondary or acquired resistance [BGB-A333 is an investigational humanised monoclonal antibody against PD-L1 that has demonstrated anti-tumour activity in xenograft models [Tislelizumab is a humanised IgG4 monoclonal antibody with high affinity and specificity for PD-1 that was engineered to minimise binding to FcγR on macrophages [Combining immune checkpoint inhibitors may help counter resistance pathways and increase the sensitivity to PD-1/PD-L1 treatment, offering the potential for improved anti-tumour responses and patient outcomes [